Magovern G J, Liebler G A, Park S B, Burkholder J A, Sakert T, Simpson K A
Department of Surgery, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212.
Ann Thorac Surg. 1989 Sep;48(3 Suppl):S33-4. doi: 10.1016/0003-4975(89)90629-2.
We reviewed 25 years (4,798 patient-years) of aortic valve replacement with the Magovern-Cromie sutureless valve. Operative mortality was 11% for isolated aortic valve replacement and 15% for aortic valve replacement with concomitant cardiac procedures. Since 1981, operative mortality has declined to 4.9%. Valve-related morbidity was in the lower expected ranges for prosthetic aortic valves: ball variance, 0.3%/patient-year; paraprosthetic leak, 0.41%/patient-year; valve endocarditis, 0.43%/patient-year; valve thrombosis, 0.04%/patient-year; and embolic events, 3.95%/patient-year. The incidence of aortic valve reoperation was 0.76%/patient-year. The 5-year, 10-year, and 20-year probability of survival corrected for normal mortality was 77%, 64%, and 52% for all discharged patients. This review confirms the Magovern-Cromie valve to be a safe, durable, and efficient prosthetic valve.
我们回顾了使用马戈文-克罗米无缝合瓣膜进行主动脉瓣置换术的25年（4798患者年）情况。单纯主动脉瓣置换术的手术死亡率为11%，同期进行心脏手术的主动脉瓣置换术的手术死亡率为15%。自1981年以来，手术死亡率已降至4.9%。人工主动脉瓣的瓣膜相关发病率处于较低预期范围：球瓣变异率为0.3%/患者年；人工瓣膜旁漏为0.41%/患者年；瓣膜心内膜炎为0.43%/患者年；瓣膜血栓形成率为0.04%/患者年；栓塞事件发生率为3.95%/患者年。主动脉瓣再次手术的发生率为0.76%/患者年。所有出院患者经正常死亡率校正后的5年、10年和20年生存率分别为77%、64%和52%。本综述证实马戈文-克罗米瓣膜是一种安全、耐用且有效的人工瓣膜。
